Tom graduated University of Brighton with a BA (Hons) degree in Broadcast Journalism, leaving as the valedictorian of the class of 2015. His final year projects and dissertation were nominated for, and won, several awards, whilst he was also the Editor-in-Chief of the university’s news site during his time at Brighton. After previously writing for a property magazine, Tom joined the Proactive team in January 2016.
Trigen Pharma will distribute and commercialise OptiBiotix’s cholesterol- and blood pressure-reducing CholBiome products in Pakistan
Takeda is reportedly preparing to launch a bid for Shire before the April 25 deadline, but Shire’s oncology unit was one of the key reasons it wanted the takeover in the first place
According to two Reuters sources with direct knowledge of the matter, Takeda has spoken with several banks about borrowing tens of billions of dollars to fund the possible acquisition of Shire
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
Tagrisso will now be the first treatment doctors use on lung cancer patients whose tumours have a specific mutation called an EFGR mutation
Motif Bio will tell leading experts at ECCMID 2018 that iclaprim is not only safe and well-tolerated, but that it does far less damage to patients’ kidneys than current treatments
ReNeuron’s human retinal progenitor cell (hRPC) therapy is being developed as a treatment for blindness-causing eye diseases such as retinitis pigmentosa
Halozyme had been using ThioBridge in some of its antibody-drug conjugate products, including HTI-1511 which had shown promise in pre-clinical trials
Of course if you’ve already done so, this article probably doesn’t apply to you…
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
As I venture into the world of equity trading, here’s the background to my story and where I’m at now